SSG
CCCC icon

Summit Securities Group’s C4 Therapeutics CCCC Stock Holding History

Summit Securities Group’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-2,122
Closed -$3.03K – 1065
2025
Q2 		$3.03K Buy
2,122
+1,967
+1,269% +$2.86K ﹤0.01% 1008
2025
Q1 		$248 Buy
+155
New +$462 ﹤0.01% 732
2024
Q4 		– Sell
-143
Closed -$1K – 672
2024
Q3 		$1K Buy
+143
New +$861 ﹤0.01% 506

Other funds holding CCCC

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Summit Securities Group's CCCC Position: Q3 2025 in Review

Summit Securities Group sold out of C4 Therapeutics (CCCC) in Q3 2025, closing a stake of 2,122 shares — an estimated $3.03K sold.

Summit Securities Group first reported a position in CCCC in Q3 2024 and held it in 3 quarters. The position peaked at $3.03K in Q2 2025. 97 funds tracked by Wall St. Rank hold CCCC as of Q3 2025.

  • Summit Securities Group reported no remaining C4 Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Summit Securities Group sold 2,122 C4 Therapeutics shares in Q3 2025, an estimated $3.03K.
  • Summit Securities Group first reported a position in C4 Therapeutics in Q3 2024 and held it in 3 quarters.
  • Summit Securities Group's C4 Therapeutics position peaked at $3.03K in Q2 2025.
  • 97 funds tracked by Wall St. Rank held C4 Therapeutics as of Q3 2025.

Based on Summit Securities Group's 13F filing for Q3 2025, filed 13 Nov 2025.